Clinical Characteristics and Treatment Outcomes of Prurigo Nodularis: A Retrospective Study

被引:1
|
作者
Taghaddos, Dana [1 ]
Savinova, Iryna [1 ]
Abu-Hilal, Mohannad [1 ,2 ,3 ,4 ]
机构
[1] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada
[2] McMaster Univ, Div Dermatol, Hamilton, ON, Canada
[3] McMaster Univ, Michael G DeGroote Sch Med, Div Dermatol, Hamilton, ON, Canada
[4] McMaster Univ, 100 Main St West, Hamilton, ON L8P 1H6, Canada
关键词
prurigo nodularis; pruritus; comorbidities; psychiatric disorders;
D O I
10.1177/12034754241227808
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Prurigo nodularis (PN) is a complex chronic skin disease characterized by severe pruritic nodules. PN is often associated with mental health disorders and chronic medical comorbidities. Until recently, PN treatment has been challenging and difficult.Objectives: This study aims to describe the demographic, clinical characteristics, and comorbidities associated with PN. Also, we aim to describe the effectiveness of systemic therapies, including methotrexate, cyclosporine, and narrow band ultraviolet (NB-UVB) in adult patients with PN.Methods: This is a retrospective chart review of adult patients diagnosed with PN at Hamilton Health Science Center and/or McMaster University in Hamilton, Ontario, between 2015 and 2023.Results: The study included 81 patients (57% female). The mean age was 52.8 years, and the mean age of PN diagnosis was 50 years. Reported symptoms included: itching (100%), dry skin (53%), pain (17%), and burning sensation (5%). Lower and upper extremities were the most common areas involved in 93% and 69%, respectively. Mental health disorders were present in 79% of patients, with depression (58%) and anxiety (52%) being the most common. Atopic dermatitis was the most common skin comorbidity noted. Treatments used included cyclosporine, and NB-UVB, and MTX, which resulted in significant improvement of pruritus in 38%, 35%, and 31% of patients, respectively, at week 16.Conclusions: PN is associated with increased risk of mental health disorders and other medical comorbidities. Cyclosporine, methotrexate, and NB-UVB therapy may be effective treatment options, however clinicians must consider the potential short- and long-term adverse effects of these treatments.
引用
收藏
页码:141 / 145
页数:5
相关论文
共 50 条
  • [21] Efficacy of Thalidomide in the Treatment of Prurigo Nodularis
    Taefehnorooz, Hamid
    Truchetet, Francois
    Barbaud, Annick
    Schmutz, Jean-Luc
    Bursztejn, Anne-Claire
    ACTA DERMATO-VENEREOLOGICA, 2011, 91 (03) : 344 - 345
  • [22] Dupilumab treatment of prurigo nodularis in an adolescent
    Giovannini, Mattia
    Mori, Francesca
    Oranges, Teresa
    Ricci, Silvia
    Barni, Simona
    Canessa, Clementina
    Liccioli, Giulia
    Lodi, Lorenzo
    Sarti, Lucrezia
    Novembre, Elio
    Azzari, Chiara
    Filippeschi, Cesare
    EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31 (01) : 104 - 106
  • [23] Dupilumab Treatment for Prurigo Nodularis and Pruritis
    Tanis, Ross
    Ferenczi, Katalin
    Payette, Michael
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (09) : 940 - 942
  • [24] Prevalence, incidence and treatment patterns of prurigo nodularis in England: a retrospective database analysis
    Bahloul, Donia
    Hudson, Richard
    Balogh, Orsolya
    Mathias, Elgan
    Heywood, Ben
    Hubbuck, Ellen
    Diribe, Onyinye
    McDonald, Robert
    Bewley, Anthony
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 (04) : 548 - 555
  • [25] Treatment-resistant prurigo nodularis
    Kolli, Sree S.
    Haidari, Wasim
    Feldman, Steven R.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2019, 12 : 345 - 346
  • [26] Prurigo nodularis: Picking the right treatment
    Saco, Michael
    Cohen, George
    JOURNAL OF FAMILY PRACTICE, 2015, 64 (04): : 221 - 226
  • [27] Treatment of prurigo nodularis with topical capsaicin
    Ständer, S
    Luger, T
    Metze, D
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 44 (03) : 471 - 478
  • [28] Dupilumab Treatment for Generalized Prurigo Nodularis
    Beck, Kristen M.
    Yang, Eric J.
    Sekhon, Sahil
    Bhutani, Tina
    Liao, Wilson
    JAMA DERMATOLOGY, 2019, 155 (01) : 118 - 120
  • [29] Treatment of Refractory Prurigo Nodularis With Lenalidomide
    Kanavy, Holly
    Bahner, Jennifer
    Korman, Neil J.
    ARCHIVES OF DERMATOLOGY, 2012, 148 (07) : 794 - 796
  • [30] Prevalence of malignancy and associated risk factors in prurigo nodularis patients: a retrospective study
    Savinova, Iryna
    Alrabai, Manal
    Taghaddos, Dana
    Abu-Hilal, Mohannad
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (06) : e113 - e114